Acorda Therapeutics Inc.

Andrew R. Blight, Ph.D. has been our Chief Scientific Officer since January 2004 and previously served as our Executive Vice President, Research and Development from 2000 to 2004, and Vice President from 1998 to 2000. Prior to joining Acorda, Dr. Blight spent approximately six years as Professor and Director of the Neurosurgery Research Laboratory at the University of North Carolina at Chapel Hill. Dr. Blight held prior academic positions at Purdue University and New York University. Dr. Blight is a leader in SCI pathophysiology research and has made several important contributions to the field, particularly on the role of demyelination in SCI. He also pioneered the therapeutic application of 4-AP in SCI animal models and in human clinical trials. Dr. Blight is a member of the editorial board of the Journal of Neurotrauma and has served as a member of the NIH NSDA review committee. He was previously Secretary, Treasurer and Vice President of the National Neurotrauma Society. Dr. Blight received his B.S. in Zoology and his Ph.D. in Zoology/Neurobiology from the University of Bristol, U.K.

David Lawrence, M.B.A. has been our Chief Financial Officer since January 2005. He previously served as our Vice President, Finance from January 2001 through 2004, and Director, Finance from 1999 to 2001. From 1991 to 1999, Mr. Lawrence held several positions for Tel-Air Communications, Inc. including Vice President and Controller. Prior to Tel-Air, he held financial management positions of Controller and Finance Manager for Southwestern Bell and Metromedia Telecommunications respectively. Mr. Lawrence received his undergraduate degree in Accounting from Roger Williams College, and an M.B.A in Finance from Iona College. Mr. Lawrence is a founding member and currently serves on the Board of Directors as Treasurer of The Brian Ahearn Children's Fund.

Jane Wasman, J.D. has been our Executive Vice President, General Counsel and Corporate Secretary since May 2004. From 1995 to 2004, Ms. Wasman held various leadership positions at Schering-Plough Corporation, including Staff Vice President and Associate General Counsel responsible for legal support for U.S. Pharmaceuticals operations, including sales, marketing and compliance; FDA regulatory matters; global research and development; and, corporate licensing and business development. She served as Staff Vice President, International in 2001 and as Staff Vice President, European Operations Legal from 1998 to 2000. Previously, Ms. Wasman specialized in litigation at Fried, Frank, Harris, Shriver & Jacobson. She also served as Associate General Counsel to the U.S. Senate Committee on Veteran's Affairs. Ms. Wasman graduated Magna Cum Laude from Princeton University and earned her J.D. from Harvard Law School.

Anthony O. Caggiano, M.D., Ph.D. has been our Vice President of Preclinical Development since February 2009. He previously served in various roles in the Preclinical and Research & Development departments since joining Acorda in 2001, directing basic research and product development efforts, coordinating external research efforts with academic and commercial collaborations, and collaborating in business development activities. Dr. Caggiano has authored papers in neuroinflammation, injury and recovery, and has been the inventor or co-inventor on multiple Acorda technologies. He also has served as a member of the National Institutes of Health (NIH) neuropharmacology Small Business Innovations Research (SBIR) grants review committee. Prior to joining Acorda, Dr. Caggiano co-founded Remote Diagnostic Imaging, a company that assembled an expert staff of radiologists to provide remote diagnostic services to understaffed hospitals. Dr. Caggiano received his undergraduate degree in interdisciplinary studies of biology, chemistry and psychology from University of Virginia, and his M.D. and Ph.D. in neurobiology from the University of Chicago.

Barclay A. Phillips, age 46, has served as our Chief Financial Officer since August 2008. Previously, he served as a member of our board of directors from 2000 until his appointment as our Chief Financial Officer in August 2008. From 1999 to August 2008, Mr. Phillips was a Managing Director of Vector Fund Management. From 1991 to 1999, Mr. Phillips served in various roles including Director of Private Placements and Biotechnology Analyst for INVESCO Funds Group, Inc. From 1985 to 1990, Mr. Phillips held positions in sales and trading with Paine Webber, Inc. and Shearson Lehman Hutton, Inc. Over the last ten years, Mr. Phillips has held board positions for a number of public and private companies and currently serves as a director of Acorda Therapeutics, Inc., a publicly traded biopharmaceutical company. Mr. Phillips received a B.A. in economics from the University of Colorado in Boulder.

Barry Greene is the President and Chief Operating Officer of Alnylam Pharmaceuticals. Barry joined Alnylam in September 2003, bringing over 15 years of experience in healthcare industries and consulting. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company's global strategy and execution for its oncology business including strategic business direction and execution, culminating in the successful approval and launch of VELCADE (bortezomib) in mid 2003. Prior to joining Millennium in February 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene's past experiences include Vice president of Marketing and Customer Services for AstraZeneca formerly AstraMerck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post merger integration; and Partner, Andersen Consulting responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene received his B.S. in Industrial Engineering from University of Pittsburgh and serves as a Senior Scholar at Duke University, Fuqua School of Business.

Ian Smith joined Vertex in November 2001. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. As Vertex’s CFO, Mr. Smith holds responsibility for a wide variety of core functions at Vertex, including Finance, Strategic Communications, Information Systems and Operations. Mr. Smith is also a member of the Executive Team at Vertex. Mr. Smith received a B.A. with honors in Accounting and Finance from Manchester Metropolitan University. Mr. Smith is a current member of the American Institute of Certified Public Accountants, the Institute of Chartered Accountants of England and Wales, and the Financial Executives Institute. Mr. Smith is a member of the Board of Directors of Acorda Therapeutics, Inc, Epix Pharmaceuticals, Inc. and TolerRx Inc. Additionally, he is a board member of the Massachusetts Biotechnology Council and is Chair of its Policy Committee.

Mr. Randall has served as our Director since September 4, 2007. Mr. Randall is an independent financial consultant and previously was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company, from 2004 to 2006. From 2002 to 2004, Mr. Randall served as Senior Vice President and Chief Financial Officer of i-STAT Corporation, a publicly-traded manufacturer of medical diagnostic devices that was acquired by Abbott Laboratories in 2004. From 1995 to 2001, Mr. Randall was Vice President and Chief Financial Officer of CFM Technologies, Inc., a publicly-traded manufacturer of semiconductor manufacturing equipment. Mr. Randall currently serves on the boards of directors of Point 5 Technologies, Inc., Rapid Micro Biosystems, Inc., Acorda Therapeutics, Inc. and Opexa Therapeutics, Inc. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University.

Michael Steinmetz, PhD, has been Managing Director of Clarus Ventures since the firm's inception in 2005. He has over 24 years of direct industry and investment experience within the healthcare sector, including being a General Partner in a healthcare venture capital firm since 1997. From 1986 to 1997, Dr. Steinmetz was an executive at Hoffmann-LaRoche where he held various positions including Vice President of Preclinical Research and Development, and Global Head of Biotechnology. Dr. Steinmetz obtained his Ph.D. summa cum laude from the University of Munich and held positions at the California Institute of Technology and the Basel Institute for Immunology. Dr. Steinmetz represents Clarus Ventures on the Board of Directors of ESBATech and Oxford Immunotec. In addition he is a member of the Board of Directors of Amphora, Biovitrum (STO:BVT), BioXell (SWX: BXLN), CGI Pharmaceuticals, ISB Accelerator, Macrogenics, Taigen ,and VLST Corp.

Sandra Panem joined Cross Atlantic Partners in 2000 as a Managing Partner. Previously, she was President of Vector Fund Management, where she was responsible for the start-up, capital raising, and management of the asset management affiliate of Vector Securities International. Operations included the management of the Vector Later-Stage Equity Fund, L.P., and Vector Later-Stage Equity Fund II, L.P., private partnerships committing $240 million to equity investments in the emerging life science and healthcare industries. Prior to joining Vector, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a $200 million mutual fund that invested in public and private biotechnology companies. Prior to Oppenheimer, Dr. Panem was Vice President at Salomon Brothers, Inc. where she acted as a member of Salomon Brothers Venture Capital, a $40 million fund focused on early and later-stage life science and technology investments. Dr. Panem was also an Assistant Professor at the University of Chicago and a Fellow at the Brookings Institution, and is the author of several books and papers concerning the commercialization of new medical technologies. Currently, she holds directorships in Acorda Therapeutics, Labcyte, and GenomeQuest. She is a director of the New York Biotechnology Association. She received a B.S. Degree in Biochemistry ('66) and a Ph.D. in Microbiology ('70) from the University of Chicago.

Mr. Rauscher has been a director since 1993 and joined the Company full-time as President and Chief Executive Officer in 2000. Before joining Oscient Pharmaceuticals, Mr. Rauscher spent 18 years at Abbott Laboratories, serving in a variety of key leadership positions including Vice President for Corporate Licensing; Vice President of Business Development; Vice President of Sales U.S. Pharmaceutical Products Division; Director of Strategic Planning for Pharmaceutical Products; and General Manager Abbott West Indies. Following his time at Abbott, Mr. Rauscher served as CEO of AmericasDoctor, a company that provides clinical research and marketing services to the pharmaceutical industry. Mr. Rauscher currently serves on the boards of directors of Acorda Pharmaceuticals and Target Discovery, Inc. Mr. Rauscher holds a M.B.A. from the University of Chicago.